Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Medicine, Endocrinology, Oncology +14

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer et al. · Annals of Oncology · 2017 · 1.3K citations · Full text

Medicine, Oncology, Breast Oncology +12

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

Paul E. Goss, James N. Ingle, Silvana Martino et al. · JNCI Journal of the National Cancer Institute · 2005 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +12

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

Clifford A. Hudis, William E. Barlow, Joseph P. Costantino et al. · Journal of Clinical Oncology · 2007 · 885 citations · Full text

Medicine, Biostatistics, Oncology +17

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Paul E. Goss, James N. Ingle, Kathleen I. Pritchard et al. · New England Journal of Medicine · 2016 · 648 citations · Full text

Medicine, Oncology, Pharmacotherapy +16